Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 31.7% year on year to $256.1 million. The company’s full-year …
Corcept (NASDAQ:CORT) Reports Bullish Q2 CY2026, Stock Jumps 17.4%
view original post